Epimedium Prenylflavonoid (EP) Extract for Osteoporosis and Cardiovascular Disease
Condition(s):Osteoporosis; Cardiovascular DiseaseLast Updated:October 14, 2016Unknown status
Hide Studies Not Open or Pending
Condition(s):Osteoporosis; Cardiovascular DiseaseLast Updated:October 14, 2016Unknown status
Condition(s):Bipolar Disorder; Substance Use DisorderLast Updated:April 19, 2017Completed
Condition(s):the Pharmacokinetic Profile of Icariin in HumansLast Updated:August 18, 2017Completed
Condition(s):Congestive Processes Of The Pelvic Organs (Prostatostasis); Erectile Dysfunction; Sexual FunctionLast Updated:June 3, 2013Unknown status
Condition(s):Alzheimer DiseaseLast Updated:August 20, 2021Completed
Condition(s):Gulf War IllnessLast Updated:March 22, 2024Completed
Condition(s):Chronic Obstructive Pulmonary DiseaseLast Updated:March 22, 2024Not yet recruiting
Condition(s):Diminished Ovarian Reserve; Infertility, FemaleLast Updated:October 27, 2022Not yet recruiting
Condition(s):COVID-19; Severe Pneumonia; Chinese MedicineLast Updated:July 7, 2021Suspended
Condition(s):CoVID-19; Chinese MedicineLast Updated:July 7, 2021Suspended
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.